Topics
2018
- All
- Products
- IR
Company
Environment
- Information
- 12.27
- 12.5
- 12.3
-
Summary of Consolidated Financial Statements for 2Q of Fiscal Year Ending March 31, 2019(Japan GAAP)
- 9.28
-
ISK Announces Approval in Japan for BRENDA, the first therapeutic drug for Pancreatitis in Dogs.
- 9.14
- 8.20
-
Summary of Consolidated Financial Statements for 1Q of Fiscal Year Ending March 31, 2019(Japan GAAP)
- 7.3
-
Notice of Results of Exercise of Voting rights at the 95th Ordinary General Meeting of Shareholders
- 6.29
-
Price Increase of Titanium Dioxide in the Asia-Pacific Region
- 6.29
- 6.14
- 6.14
- 6.13
-
Summary of Consolidated Financial Statements for Fiscal Year Ended March 31, 2018 (Japan GAAP)
- 4.2
- 3.30
-
Price Increase of Titanium Dioxide in the Asia-Pacific Region
- 2.15
- 2.15
-
Summary of Consolidated Financial Statements for 3Q of Fiscal Year Ending March 31, 2018(Japan GAAP)
- 12.5
- 12.3
-
Summary of Consolidated Financial Statements for 2Q of Fiscal Year Ending March 31, 2019(Japan GAAP)
- 9.14
- 8.20
-
Summary of Consolidated Financial Statements for 1Q of Fiscal Year Ending March 31, 2019(Japan GAAP)
- 7.3
-
Notice of Results of Exercise of Voting rights at the 95th Ordinary General Meeting of Shareholders
- 6.29
- 6.14
- 6.14
- 6.13
-
Summary of Consolidated Financial Statements for Fiscal Year Ended March 31, 2018 (Japan GAAP)
- 4.2
- 2.15
- 2.15
-
Summary of Consolidated Financial Statements for 3Q of Fiscal Year Ending March 31, 2018(Japan GAAP)